Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Rescue of Hippo coactivator YAP1 triggers DNA damage–induced apoptosis in hematological cancers
Francesca Cottini, Teru Hideshima, Chunxiao Xu, et al.
Nature Medicine (2014) Vol. 20, Iss. 6, pp. 599-606
Open Access | Times Cited: 292

Showing 1-25 of 292 citing articles:

Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer
Fa‐Xing Yu, Bin Zhao, Kun‐Liang Guan
Cell (2015) Vol. 163, Iss. 4, pp. 811-828
Open Access | Times Cited: 1951
YAP/TAZ at the Roots of Cancer
Francesca Zanconato, Michelangelo Cordenonsi, Stefano Piccolo
Cancer Cell (2016) Vol. 29, Iss. 6, pp. 783-803
Open Access | Times Cited: 1645
The Biology of YAP/TAZ: Hippo Signaling and Beyond
Stefano Piccolo, Sirio Dupont, Michelangelo Cordenonsi
Physiological Reviews (2014) Vol. 94, Iss. 4, pp. 1287-1312
Closed Access | Times Cited: 1551
The emerging roles of YAP and TAZ in cancer
Toshiro Moroishi, Carsten Gram Hansen, Kun‐Liang Guan
Nature reviews. Cancer (2015) Vol. 15, Iss. 2, pp. 73-79
Open Access | Times Cited: 1052
The Hippo Pathway: Biology and Pathophysiology
Shenghong Ma, Zhipeng Meng, Rui Chen, et al.
Annual Review of Biochemistry (2018) Vol. 88, Iss. 1, pp. 577-604
Closed Access | Times Cited: 1042
The Hippo Signaling Pathway in Development and Disease
Yonggang Zheng, Duojia Pan
Developmental Cell (2019) Vol. 50, Iss. 3, pp. 264-282
Open Access | Times Cited: 718
Targeting signalling pathways and the immune microenvironment of cancer stem cells — a clinical update
Joseph Clara, Cecilia Monge, Yingzi Yang, et al.
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 4, pp. 204-232
Closed Access | Times Cited: 623
Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway
Jung-Soon Mo, Zhipeng Meng, Young Chul Kim, et al.
Nature Cell Biology (2015) Vol. 17, Iss. 4, pp. 500-510
Open Access | Times Cited: 491
Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets
Jae Hyung Park, Woo Yang Pyun, Hyun Woo Park
Cells (2020) Vol. 9, Iss. 10, pp. 2308-2308
Open Access | Times Cited: 401
The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity
Toshiro Moroishi, Tomoko Hayashi, Weiwei Pan, et al.
Cell (2016) Vol. 167, Iss. 6, pp. 1525-1539.e17
Open Access | Times Cited: 384
The Hippo signalling pathway and its implications in human health and diseases
Minyang Fu, Yuan Hu, Tianxia Lan, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 332
YAP/TAZ Signaling and Resistance to Cancer Therapy
Chan D.K. Nguyen, Chunling Yi
Trends in cancer (2019) Vol. 5, Iss. 5, pp. 283-296
Open Access | Times Cited: 315
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Jonathan Pol, Erika Vacchelli, Fernando Aranda, et al.
OncoImmunology (2015) Vol. 4, Iss. 4, pp. e1008866-e1008866
Open Access | Times Cited: 276
Pathogenesis beyond the cancer clone(s) in multiple myeloma
Giada Bianchi, Nikhil C. Munshi
Blood (2015) Vol. 125, Iss. 20, pp. 3049-3058
Open Access | Times Cited: 260
Analysis of the role of the Hippo pathway in cancer
Yanyan Han
Journal of Translational Medicine (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 260
Disease implications of the Hippo/YAP pathway
Steven W. Plouffe, Audrey W. Hong, Kun‐Liang Guan
Trends in Molecular Medicine (2015) Vol. 21, Iss. 4, pp. 212-222
Open Access | Times Cited: 211
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
Richard Cunningham, Carsten Gram Hansen
Clinical Science (2022) Vol. 136, Iss. 3, pp. 197-222
Open Access | Times Cited: 208
YAP/TAZ as therapeutic targets in cancer
Francesca Zanconato, Giusy Battilana, Michelangelo Cordenonsi, et al.
Current Opinion in Pharmacology (2016) Vol. 29, pp. 26-33
Open Access | Times Cited: 204
Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription
Qinjunjie Chen, Haibo Wang, Zheng Li, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 1, pp. 135-147
Open Access | Times Cited: 172
YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches
Stefano Piccolo, Tito Panciera, Paolo Contessotto, et al.
Nature Cancer (2022)
Open Access | Times Cited: 146
Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity
Joel D. Pearson, Katherine Huang, Marek Pacal, et al.
Cancer Cell (2021) Vol. 39, Iss. 8, pp. 1115-1134.e12
Open Access | Times Cited: 120
YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance
Frank Szulzewsky, Eric C. Holland, Valeri Vasioukhin
Developmental Biology (2021) Vol. 475, pp. 205-221
Open Access | Times Cited: 113
Insights into recent findings and clinical application of YAP and TAZ in cancer
James Franklin, ZhengMing Wu, Kun‐Liang Guan
Nature reviews. Cancer (2023) Vol. 23, Iss. 8, pp. 512-525
Closed Access | Times Cited: 110
Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer
Shenghong Ma, Tracy Tang, Gary D. Probst, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 96
Therapeutic targeting of TEAD transcription factors in cancer
Ajaybabu V. Pobbati, Ramesh Kumar, Brian P. Rubin, et al.
Trends in Biochemical Sciences (2023) Vol. 48, Iss. 5, pp. 450-462
Closed Access | Times Cited: 82
Page 1 - Next Page

Scroll to top